Tim Andrews is a seasoned legal executive with extensive experience advising biotech and pharmaceutical companies through all stages of growth, including IPOs and high-profile M&A transactions. Mr. Andrews served as the General Counsel and Secretary of Prometheus Biosciences from 2020 through the company’s IPO and acquisition by Merck in June 2023. Prior to Prometheus, Mr. Andrews served as General Counsel and Secretary for Sienna Biopharmaceuticals, Inc. (Nasdaq: SNNA) from 2016 to 2019, where he led the acquisition of a UK-based biotech company and the company‘s subsequent IPO. He served as Senior Corporate Counsel and Assistant Secretary at Allergan, Inc. from 2011 until the company’s $70.5 billion acquisition by Actavis in 2015, during which time he was lead counsel on Allergan’s U.S. and international business development transactions.

Earlier in his career, Mr. Andrews was a corporate attorney at Latham & Watkins LLP and a Business Analyst at Deloitte Consulting. He holds a B.A. in Political Economy from the University of California, Berkeley and a J.D. from Loyola Law School, Los Angeles.